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DNA polymorphisms in a region on chromosome 5q33.1 which contains two genes, immunity related GTPase
related family, M (IRGM) and zinc finger protein 300 (ZNF300), are associated with Crohn’s disease (CD). The
deleted allele of a 20 kb copy number variation (CNV) upstream of IRGMwas recently shown to be in strong link-
agedisequilibrium (LD)with theCD-associatedsinglenucleotidepolymorphismsand is itself associatedwithCD
(P < 0.01). Thedeletionwascorrelatedwith increasedor reducedexpressionof IRGM in transformedcells ina cell
line-dependentmanner, and hasbeenproposedas a likely causal variant.We report here that small insertion/del-
etion polymorphisms in the promoter and 50 untranslated region of IRGM are, together with the CNV, strongly
associated with CD (P 5 1.37 3 1025 to 1.40 3 1029), and that the CNV and the 50-untranslated region variant
2308(GTTT)5 contribute independently to CD susceptibility (P 5 2.6 3 10
27 and P 5 2 3 1025, respectively).
We also show that the CD risk haplotype is associated with a significant decrease in IRGM expression (P <
10212) in untransformed lymphocytes from CD patients. Further analysis of these variants in a Japanese CD
case–control sample and of IRGM expression in HapMap populations revealed that neither the IRGM inser-
tion/deletion polymorphisms nor the CNV was associated with CD or with altered IRGM expression in the
Asian population. This suggests that the involvement of the IRGM risk haplotype in the pathogenesis of CD
requires gene–gene or gene–environment interactions which are absent in Asian populations, or that none of
the variants analysed are causal, and that the true causal variants arose after the European–Asian split.
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INTRODUCTION
Genome-wide association scans (GWAS) have been very suc-
cessful in identifying susceptibility loci for Crohn’s disease
(CD), one form of chronic inflammatory bowel disease
[reviewed in (1)]. The discovery by the Wellcome Trust Case
Control Consortium (WTCCC) that single nucleotide poly-
morphisms (SNPs) near the immunity related GTPase related
family, M (IRGM) gene on chromosome 5q33.1 were associated
with CD provided a potentially important clue to its pathogenesis
(2,3). IRGM is an atypical member of the IRG family of p47
immunity-related GTPase genes (4,5) which are characteristi-
cally induced by interferon and provide resistance to intracellular
pathogens. The gene has had an unusual evolutionary history,
with disruption of the open reading frame generating a non-
functional pseudogene in Old and New World monkeys and
apparent restoration of a truncated version in humans and
African great apes (5). Although human IRGM lacks
interferon-inducible elements in its promoter, reduction of its
expression in culture was associated with impairment of induc-
tion of autophagy and clearance of intracellular bacteria (6,7).
The region of association with CD also includes ZNF300, a
gene whose product is reported to bind the promoter of the
gene encoding interleukin 2 receptor beta-chain (8) involved in
T cell-mediated immunity. ZNF300 is expressed predominantly
in heart, skeletal muscle and brain (9), with weaker expression in
the small intestine. In addition to IRGM itself and ZNF300,
which is transcribed in the opposite direction to IRGM (right to
left in Fig. 1), the region also contains LOC134466, a pseudo-
gene of ZNF300 (Fig. 1). The nearest gene other than IRGM of
functional interest at this locus is TNIP1, which is located
80 kb distal to the region of association. TNIP1 encodes the
tumour necrosis factor alpha inducing protein 3 (TNFAIP3)
interacting protein, which inhibits NF-kB activation by tumour
necrosis factor (10), and could conceivably be regulated by
sequences within the region of association with CD. The original
report (2) and replication (3) of the association of this locus with
CD have been confirmed in several other studies (7,11–16).
The association of this locus with CD is clearly robust, but
significant questions remain regarding the nature of its contri-
bution to pathogenesis. In particular, we need to establish
whether the association is driven by the IRGM gene itself or
by other genes in the region, and to identify the causal variants
in order to understand what effects they have on gene
expression and function. Identification of causal variants also
has the potential to provide more precise genetic markers of
disease susceptibility (1,17). We reported previously (2) that
extensive re-sequencing of the IRGM coding region did not
reveal any obvious causal variants. A recent study by McCarroll
et al. (7) showed that the deletion allele of a 20 kb copy number
variant (CNV) that maps 1.6 kb upstream of IRGM is comple-
tely correlated (r2 ¼ 1.0) with the CD risk allele at the SNP
rs13361189 (3). They also showed that the CNV deletion
allele itself was significantly associated with CD in 172 cases
and 344 controls (P , 0.01), and that the risk haplotype was
correlated with altered expression levels of IRGM in cultured
cells. IRGM expression from the risk haplotype was reduced
in HeLa cells and in lymphoblastoid cell lines from 10 individ-
uals, but increased in a colon carcinoma cell line and in smooth
muscle cells. They therefore proposed that the CD association
results from altered regulation of IRGM, and that the common
deletion polymorphism is likely to be the causal variant. This
was further supported by the fact that the strongest association
with CD from this region in a North American GWAS was with
rs13361189 (p 3.02  1024) just upstream of IRGM (7,18).
The fact that IRGM plays a role in autophagy, and that SNPs
in another autophagy-related gene, autophagy 16-like isoform
1 (ATG16L1), are also associated with CD (2,18,19), add
weight to the hypothesis that IRGM is the causal gene at this
locus. However, given the extent of the association signal
and the lack of experimental evidence that the CNV itself is
directly responsible for the regulation of IRGM expression,
we have undertaken a detailed genetic analysis of the contri-
bution of this locus to susceptibility to CD. We have used
the results of a large meta-analysis of three GWAS in CD
which combined data from 3230 cases and 4829 controls
(16) to provide a more robust estimate of the extent of the
association across this locus. In addition we have carried out
fine mapping in the region of association, and screening of
all exon sequences, including ZNF300 and the previously neg-
lected IRGM promoter and exon 1, for novel genetic variants.
This was followed by an association study and conditional
analysis of novel and known variants in a large UK-based
case–control (1800 versus 2000) cohort. Finally, we investi-
gated the expression of candidate genes and the association
of candidate variants in different populations, and examined
IRGM expression in a physiologically relevant primary
tissue (lymphocytes) from CD patients of known risk
Figure 1. Association of 35 SNPs at the IRGM-ZNF300 locus with CD (data from Ref. 16) indicated by –log of P-value. The physical location of the SNPs on
chromosome 5 in Mbp is given on the x-axis with the relative position of the genes and CNV underneath.
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genotypes. Our results provide novel insights into the contri-
bution of sequence variants at this locus to disease suscepti-
bility.
RESULTS
Disease association at the IRGM locus
The WTCCC study (2) found strong association of 11 SNPs
with CD, spanning a 110 kb region of chromosome 5 (from
rs13361189 at 150 203 580 bp to rs931058 at 150 313 891 bp,
NCBI build 36). In addition, a meta-analysis of three GWAS
in CD (16) included 35 SNPs in the 200 kb interval from
150 150 000 bp to 150 350 000 bp on chromosome 5. The
results, which are plotted onto the physical map of the region
in Figure 1, show strong association with CD from the SNP
rs2112637 at position 150 162 627 bp to SNP rs931058 at
150 313 891 bp. The most significant SNPs were rs11747270
and rs1000113 (P ¼ 6.37  10211 and 7.5  10211), which
are both located within the 42 kb of non-coding DNA
between IRGM and ZNF300, and rs13361189 (P ¼ 8.17 
10211) just upstream of IRGM. These data suggest that,
purely on the basis of physical location, both IRGM and
ZNF300 should be considered as candidates for the source of
the association signal.
In order to evaluate the extent of the association signal and
to detect any possible additional associated common haplo-
types not well tagged on the Affymetrix 500K SNP array,
genotypes from the HapMap panel, from Caucasian Europeans
from Utah (CEU), were used to identify eight additional SNPs
which provided more complete tagging of the region. These
were genotyped in 931 CD cases and 976 controls (Sup-
plementary Material, Table S1). The only new tagging SNP
that was associated with CD was rs12659118, located within
LOC134466 (MAFCD ¼ 0.116, MAFCON ¼ 0.084, P ¼
0.0017). This SNP is in strong linkage disequilibrium (LD)
with rs13361189 in controls (r2 ¼ 0.79), and was not associ-
ated with CD in individuals who did not carry the risk allele
at rs13361189 (MAFCD ¼ 0.019, MAFCON ¼ 0.016, P ¼
0.55).
Sequencing IRGM and ZNF300
The strong association across the region suggested that
re-sequencing the IRGM and ZNF300 genes to screen for poss-
ible causal variants was warranted. The six exons and adjacent
splice sites of the ZNF300 gene were sequenced (see Materials
and Methods) in 45 cases. The only variant detected was a
synonymous SNP, rs17800771, which is in strong LD with
the SNP rs2290989 (r2 ¼ 0.88) that was genotyped in the
WTCCC scan and was not associated with CD (P ¼ 0.42).
Previous re-sequencing of the coding regions of IRGM in
more than 700 CD cases detected two non-synonymous
SNPs, E17D and T94K, which were not associated with CD
in a sample of 769 cases and 705 controls, and an exonic
synonymous SNP (L105 or rs10065172), which was associ-
ated (3). We extended this study by genotyping E17D and
T94K in an expanded panel of 1400 cases and 1800 controls.
Neither E17D (MAFCD ¼ 0.0028, MAFCON ¼ 0.0013) nor
T94K (MAFCD ¼ 0.044, MAFCON ¼ 0.042) were associated
with CD (P ¼ 0.19 and 0.86, respectively).
In view of the lack of association of potential functional
coding variants we investigated the upstream region of this
gene for variants that might affect IRGM expression. The
human and ape versions of IRGM are unusual in that the
ancestral promoter has been supplanted by the promoter
element of an inserted endogenous retrovirus (ERV9) long
terminal repeat (LTR) 1.6 kb upstream of the initiation
codon (4,5). This has also introduced an upstream exon
(exon 1) which encodes the first 695 bp of the 1.11 kb 50
untranslated region (UTR) of IRGM and contains the ERV9
U5 repeat elements (Fig. 2). A 2.9 kb region spanning the
IRGM initiation codon, the entire 50-UTR including exon 1
and intervening intron, ERV9 LTR and promoter were
sequenced in 94 unrelated individuals, including 43 cases of
CD. Two insertion/deletion (indel) polymorphisms were
detected (Fig. 2). One is a 4 bp insertion in the promoter
region of the ERV9 LTR (21644insTGGG) and the other is
a 12 bp insertion in exon 2 (308 bp upstream of the initiation
codon) which has also been detected in the Ghanaian popu-
lation (20). The 2308 variant is a microsatellite which has a
common allele (GTTT)2 and two additional alleles, (GTTT)4
and (GTTT)5. The 21644ins is located between three
closely juxtaposed transcription factor (TF) binding sites for
nuclear factor gamma, myeloid zinc finger 1 and GATA
binding protein 2. The region upstream of IRGM also contains
a CNV (21–23) which is correlated with altered expression of
IRGM (6). Fine-mapping of the CNV on a high-resolution
array and sequencing of the breakpoint revealed a deletion
of 20 101 bp, spanning from 150 183 354 to 150 203 455 on
chromosome 5 (NCBI 36, Fig. 2). The position and size of
the CNV, as we identified it, is in close agreement with
what has been reported previously (5,7).
Association of IRGM promoter and CNVs with CD
The association of the IRGM promoter indel, microsatellite
and upstream CNV with CD was investigated by analysis of
these variants together with a strongly associated and repli-
cated SNP from the WTCCC study (rs13361189) (2,3) and
the synonymous coding SNP (L105 or rs10065172) in 1848
CD cases and 2025 population controls. Mapping of the
CNV breakpoints enabled the design of a robust, qualitative
assay with a common forward primer positioned immediately
upstream of the CNV and two allele-specific primers, one
located in the deleted region and the other immediately down-
stream of the CNV [Materials and Methods and (24)]. The
results (Table 1) show that all these variants are strongly
associated with CD, with the most significant signals coming
from the deletion allele of the CNV and from the WTCCC
SNP, rs13361189 (Pallele ¼ 1.4  1029 and 3.7  1029,
respectively). However, allele frequencies and odds ratios
for all the variants with the exception of the CD-associated
allele 2308(GTTT)5 are very similar. As reported by McCar-
roll et al. (7), the CNV was in strong LD with rs13361189 and
rs10065172 (Fig. 3). The promoter variant 21644ins was also
in strong LD with the CNV and both of these SNPs (r2 . 0.9
in cases and controls), whereas 2308(GTTT)5 was in moder-
ate LD with the other four variants.
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The existence of multiple highly correlated variants (some
of which have potential functional significance) which are
all associated with disease risk raises the question as to
which, if any, of these might be a causal variant and thus
driving the association at this locus. We investigated this by
conditional logistic regression analysis across the five loci
(Table 2). The analysis showed that the CNV remained
highly significantly associated with disease when conditioned
on the variants at 21644 and 2308; that is to say, when all
the association at either of the two variants was accounted
for, there remained significant independent association with
the CNV (P ¼ 1.6  1025 and 2.6  1027, respectively).
However, the effect of the CNV on disease was not significant
when conditioned on the two SNPs rs13361189 or rs10065172
(P ¼ 0.221, 0.251). Thus the effect of the CNV could not be
distinguished from the effect of either SNP, which is consist-
ent with the strong LD between these three variants. Similarly,
the two SNPs showed an association that was independent of
the variants at 21644 and 2308 but not of each other or the
CNV. The 21644 variant showed significant independent
association when conditioned on either the CNV (P ¼ 3.1 
1024) or on 2308 (P ¼ 9.3  1026), but was not significant
or marginally so when conditioned on the two SNPs (P ¼
0.142, 0.047). However, 2308 showed highly significant inde-
pendent association when conditioned on any of the other four
variants (P ¼ 9.4  1026 to 2.38  1024). The apparently
independent effect from 21644 appeared to be due to two
very rare haplotypes (haplotypes 10 and 11 in Table 3)
which had a combined frequency of 0.0035 in CD cases but
were not present in controls; one of these (haplotype 10 in
Table 3) contained the risk (del) allele at the CNV and the
common (del) allele at 21644. In our case–control study
the 2308(GTTT)4 (rare 8 bp insertion) allele was detected
in only four CD cases and in none of the controls (haplotype
11 in Table 3). It is possible that these very rare haplotypes,
that were only seen in CD cases (n ¼ 7), were over-inflating
the test statistic. The conditional regression analysis was there-
fore repeated with the exclusion of rare haplotypes with a fre-
quency ,0.005 (Table 4). In this analysis the independent
effect observed previously for 21644 disappeared and thus
the effects of the CNV, 21644 and the two SNPs were indis-
tinguishable. However, all remained significant when con-
ditioned on the 2308, and conversely, 2308 retained highly
significant independent association with CD when conditioned
against all other four variants (P ¼ 4.24  1025 to 3.9 
1024). At least part of the independent effect for the 2308
variant appeared to be due to a haplotype that had the
non-risk (non-deleted) allele at the CNV but the high risk
(GTTT)5 allele at -308 (haplotype 3 in Table 3); this haplotype
had a frequency of 5.2% in CD cases and 4.1% in controls and
was associated with CD (P ¼ 0.038; Table 3).
The analysis was repeated on a subset (75%) of cases (1265)
and controls (1609) with complete genotypes for all five loci
and produced very similar results (not shown). The regression
analysis suggests that the haplotype represented by the CNV,
the two SNPs and 21644ins constitutes one independent
effect on disease risk, and that 2308(GTTT)5 may be another.
Analysis of IRGM variants in other populations
The difficulties in identifying the origin of association signals
at the IRGM locus in European populations led us to investi-
gate the frequency of these variants and LD structure in
other populations, since weaker LD might facilitate fine-
mapping studies. We genotyped the CNV, promoter variant
and microsatellite in five of the HapMap3 populations for
whom genotype data were available for the original associated
SNP rs13361189. These were the Han Chinese from Beijing
(CHB), the Japanese from Tokyo, Japan (JPT), the Yoruba
in Ibadan, Nigeria (YRI) and two other African populations,
the Maasai in Kinyawa, Kenya (MKK) and Luhya in
Webuye, Kenya (LWK). We found that the frequencies of
Figure 2. The structure of IRGM showing the location of the upstream CNV on chromosome 5. Horizontal arrows represent the relative positions of the three
primers for the CNV PCR assay which uses the common left primer (black), and either the insertion right primer (grey) or deletion right (black). The position of
the two risk SNPs are indicated by vertical arrows. The IRGM region consisting of the single coding exon 2 and upstream un-translated exon 1 containing the
promoter (P) and U3/U5 repeats of the ERV9LTR is expanded above to indicate the relative positions of the two insertion/deletion polymorphisms (boxed).
Potential TF binding sites adjacent to the 21644ins are underlined. The coding sequence (CDS) of IRGM is shaded in dark grey.
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all four CD risk variants were much higher in all these popu-
lations compared with the white UK population (Fig. 4).
Indeed, the CNV deletion (CD risk) allele is the common
allele in the YRI population, whereas the 2308(GTTT)5 CD
risk allele is the common allele in both Asian populations.
Also of interest is that the 2308(GTTT)4 allele, which is
very rare in European populations, has a frequency of
8–18% in the African populations; the frequencies of the
2308 alleles in the Yoruba group are similar to those reported
in the West African population of Ghana (20). We observed
that LD between the CNV and rs13361189 was lower in the
JPT (r2 ¼ 0.88) and CHB (r2 ¼ 0.84) compared with Eur-
opeans (r2 ¼ 0.95), and was substantially lower in two of
the three African populations (YRI: r2 ¼ 0.70, LWK: r2 ¼
0.66). LD between the CNV and both the 21644 and the
2308 variants was also lower in Asian and African popu-
lations as compared with Europeans (Supplementary Material,
Fig. S1). The reduction in LD observed across this locus in
Asian and African populations is consistent with the substan-
tial differences in allele frequencies, and suggested that inves-
tigation of the association of these variants with CD in other
populations might provide further insight into their contri-
bution to CD.
Association study of IRGM variants in Japanese CD cases
and controls
An African case/control sample was not available, so we
focused our analysis on a well-studied Japanese collection. A
recent analysis of 484 Japanese CD cases and 470 controls
from this collection found no association of SNPs rs13361189
or rs4958847 at the IRGM locus with CD (25). We genotyped
the CNV, variants at 21644 and 2308 and SNPs rs13361189
and rs10065172 in the same 484 CD cases and in an expanded
set of 933 Japanese controls. The results (Table 5) show no
association of these variants with CD, with the exception of a
weak protective effect for the 2308(GTTT)5 allele (P ¼
0.03), which is the risk allele in Europeans. As in the UK popu-
lation, there was very strong LD between the CNV, 21644,
rs13361189 and rs10065172 (r2. 0.95), with 2308 again
being in weaker LD with the other four variants (r2 ¼ 0.48–
0.55). One obvious explanation for this lack of association is
inadequate power to detect small effects. Reported odds ratios
for the IRGM locus were 1.33 and 1.34 in two meta-analyses
(15,16) and 1.44 in a recent study of a large Dutch–Belgian
cohort (13). Power to detect association at the CNV in this Japa-
nese case/control sample with an allele frequency in controls of
0.38 is .90% for an OR ¼ 1.35, P ¼ 0.05, so the study is well
powered assuming that the effect size in Japanese is similar to
that in European populations.
Effect of the risk haplotype on IRGM and ZNF300
expression
In view of the lack of obvious pathogenic or disease-associated
variants in the coding regions of IRGM and the presence of
several potential regulatory variants upstream of the ATG start
codon (including 21644, 2308 and the CNV), we then
addressed the question of whether a correlation existed
between the risk haplotype and expression levels of IRGM.
McCarroll et al. (7) reported variable effects on IRGM
expression in different cell lines and cell types (7). We analysed
IRGM expression from the high- and low-risk haplotypes by
sequencing cDNA and genomic DNA prepared from primary
lymphocytes of eight CD patients who were heterozygous for
the risk haplotype, and comparing the relative expression of
the C (low-risk) and T (high-risk) alleles of the exonic SNP
rs10065172 in these individuals (Supplementary Material,
Fig. S2). This showed that expression of the T allele was mark-
Table 1. Association of IRGM variants with Crohn’s disease analysed in 1848 CD cases and 2025 population controls
Variant Risk allele Risk allele frequency Pallele Ptrend OR (95% CI)
Cases Controls
CNV Del 0.115 0.073 1.40  1029 1.9  1029 1.66 (1.41–1.95)
rs13361189 C 0.115 0.075 3.73  1029 5.10  1029 1.65 (1.40–1.95)
21644 Ins 0.108 0.073 4.20  1027 4.20  1027 1.53 (1.38–1.80)
2308 (GTTT)5 0.149 0.111 1.37  1025 2.77  1026 1.37 (1.19–1.58)
(GTTT)4 0.001 0.000 0.0048
a n/a n/ab
rs10065172 T 0.107 0.071 1.04  1027 1.01  1027 1.56 (1.33–1.85)
Results show P-values for allele specific association tests and the genotype trend test which can also account for multi-allelic genotypes.
aFishers exact test.
bNot possible due to absence in controls.
Figure 3. Linkage disequilibrium of IRGM variants in UK CD cases and con-
trols.
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edly lower than the C allele (C/T peak height ratio in cDNA:
1.82–353.44) in seven of eight samples tested (P ¼ 0.015).
We also analysed primary lymphocytes in 25 CD patients of
defined IRGM genotype and measured expression of both
genes by real-time quantitative RT–PCR. The risk haplotype
is relatively rare in European populations, and expression
levels of IRGM varied widely between individuals. Nonetheless,
we found significantly lower IRGM expression (P, 10212) in
homozygotes and heterozygotes for the risk haplotypes at all
three loci, i.e. the CNV, 21644ins and 2308(GTTT)5 than in
homozygotes for the absence of the risk haplotype (Fig. 5).
Most individuals tested had the same genotype for all three var-
iants as a result of the strong LD between them, so we could not
test for independent effects of the variants on expression.
We next analysed the effect of IRGM genotype on IRGM
expression using microarray expression data from lymphoblas-
toid cell lines in the Asian and extended African HapMap popu-
lations (26; Stranger et al., in preparation). The risk alleles for the
CNV, rs13361189 and 2308(GTTT)5 were associated with a
highly significant reduction in expression of IRGM in the YRI
population and in pooled data from the three African populations
(YRI, MKK, LWK), with much weaker association for
21644ins (Table 6). However, there was no association of any
of the loci with altered IRGM expression in the Japanese or
Chinese populations. Interestingly, overall expression of IRGM
was higher in the JPT and CHB samples than in the three
African populations, with the lowest expression across all popu-
lations observed in Europeans (P, 10215; Fig. 6).
Table 2. Conditional logistic regression and haplotype analysis of IRGM variants in CD cases/controls, all haplotypes
Conditional locus
CNV rs13361189 21644 2308 rs10065172
Test locus CNV 1.0 0.221 1.6  1025 2.6  1027 0.251
rs13361189 0.361 1.0 0.005 3.88  1026 0.388
21644 3.1  1024 0.142 1.0 9.3  1026 0.047
2308 9.4  1026 2.38  1024 5.8  1025 1.0 1.50  1025
rs10065172 0.392 0.49 1.58  1023 1.12  1027 1.0
This is a test of multiple haplotypes (see Materials and Methods).
Table 3. Haplotypes analysis (all haplotypes)
Haplotype CNV rs13361189 21644 2308 rs10065172 Counta Frequency OR(95%CI) P
Case Control Case Control
1 INS T DEL (GTTT)2 C 1668 2762 0.831 0.884 ref ref
2 DEL C INS (GTTT)5 T 191.5 207.8 0.095 0.066 1.53 (1.24–1.88) 6.18  1025
3 INS T DEL (GTTT)5 C 104.5 130.3 0.052 0.042 1.33 (1.02–1.73) 0.038
4 INS C DEL (GTTT)2 C 6.003 6.006 0.003 0.002 1.66 (0.53–5.14) 0.386
5 DEL C INS (GTTT)2 T 28.46 5.214 0.014 0.002 9.04 (3.47–23.53) 4.76  1028
6 DEL C INS (GTTT)5 C 0 4.906 0 0.002 n/a 0.032
7 DEL T INS (GTTT)5 T 1.003 3.006 0.0005 0.001 0.55 (0.06–5.32) 0.591
8 INS T DEL (GTTT)2 T 0 3.005 0 0.001 n/a 0.092
9 DEL C INS (GTTT)2 C 0 2.099 0 0.0007 n/a 0.161
10 DEL T DEL (GTTT)2 C 3 0 0.0015 0 n/a
b 5.20  1023
11 DEL C DEL (GTTT)4 T 4 0 0.002 0 n/a
b 1.55  1022
Potential risk alleles are italicized.
aNon-integer haplotype counts are due to maximum likelihood estimation.
bOR over-inflated due to lack of controls with this haplotype (OR  4  106).
Table 4. Conditional logistic regression and haplotype analysis of IRGM variants in CD cases/controls but excluding rare haplotypes (f , 0.005)
Conditional locus
CNV rs1331189 21644 2308 rs10065172
Test locus CNV 1 1 1 2.6  1027 1
rs13361189 1 1 1 3.88  1026 1
21644 1 1 1 9.3  1026 1
2308 2.0  1025 9.76  1024 3.9  1024 1 4.24  1025
rs10065172 1 1 1 1.12  1027 1
This is a test of multiple haplotypes (see Materials and Methods).
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In addition to these quantitative effects, we noted that the
2308(GTTT)5 allele potentially strengthens an alternative
splice acceptor site 139 bp [or 151 bp on the (GTTT)5 allele]
downstream of the canonical splice site (Fig. 2 and Sup-
plementary Material, Fig. S3) by extending its polypyrimidine
tract. The splicing of IRGM mRNA was therefore investigated
by RT–PCR in four individuals with three possible genotypes
at 2308: (GTTT)5/(GTTT)5, (GTTT)5/(GTTT)2 and (GTTT)2/
(GTTT)2. The identity of each mRNA was determined by
sequencing of gel-extracted products. The 2308(GTTT)5
resulted, as predicted, in use of the alternative splice site
with removal of 139 bp from the 50 untranslated region of
the IRGM transcript (Supplementary Material, Fig. S3).
Finally, we investigated the expression of the other gene at
this locus, ZNF300, since it remains a possible source of the
association with CD. We looked for a correlation between
the risk haplotype and ZNF300 expression in lymphocytes
from the same 25 CD patients that showed a correlation for
IRGM but found none (P ¼ 0.10 for patients typed for the
CNV, data not shown). Similarly, analysis of microarray
expression data from 141 HapMap samples did not detect sig-
nificant correlation between the risk haplotype and ZNF300
expression (P ¼ 0.45). This does not exclude possible qualitat-
ive effects of the risk haplotype on ZNF300 expression.
DISCUSSION
In this study, we have addressed a question generic to the
follow-up of GWAS in complex disease, which is how to
define the causal genes and variants that are driving an associ-
ation at a specific locus. At the IRGM locus, very significant
association of SNPs with CD is seen across an interval
which includes two known genes, IRGM and ZNF300. The
biological evidence for the role of IRGM in autophagy,
coupled with the correlation of the risk haplotype with
altered IRGM expression, constitutes strong support for its
role in the pathogenesis of CD. However, since the strongest
association signals extend from just upstream of IRGM to a
position midway between IRGM and ZNF300, and since
IRGM does not contain an obvious functional variant, the
ZNF300 gene cannot be formally excluded as the source of
the association signal. The strong LD between the CNV
upstream of IRGM and SNPs associated with CD, and the cor-
relation of the deletion allele with altered IRGM expression
(7), further supports a primary role for IRGM in pathogenesis
and for the deletion as the causal variant. However, functional
evidence for the role of this gene in intestinal inflammation
and for a direct regulatory effect of the CNV (as opposed to
association with altered IRGM expression) is needed. We
have sought to address the question of which gene and
which variants might be driving the association by sequencing
the upstream region of IRGM and the coding region of
ZNF300 to look for other potential causal variants, and by con-
ditional analysis of the most strongly associated variants in a
well powered sample of CD cases and controls. In addition
we have investigated association of these variants with
IRGM expression in CD cases from the UK as well as in
five other populations from Africa and East Asia and carried
out a case–control analysis in a Japanese population.
Sequencing of all the exons and adjacent splice sites of
ZNF300 did not reveal any functionally relevant or
CD-associated variants. However, sequencing of the 50-UTR,
intron and complex ERV9-derived promoter region of IRGM
identified two insertion/deletion polymorphisms, one of
which is novel and located within the proximal promoter
(c.IRGM 21644) between three TF binding sites. This
variant is strongly associated with CD but is in tight LD
with the CNV. Another indel at c.IRGM 2308, has been pre-
viously described as a tetranucleotide repeat (microsatellite) in
a Ghanian population (20). We found that the 2308(GTTT)5
allele was common in the UK population and was also signifi-
cantly associated with CD. We also detected the 8 bp insertion
allele 2308(GTTT)4, which had a frequency of 0.1% in CD
cases and 0% in controls. This suggested that both alleles
were possible new CD risk alleles, which was supported by
the multi-allelic association test. Conditional regression analy-
sis of our data provided highly significant support for an inde-
pendent effect for the 2308 microsatellite polymorphism. The
2308(GTTT)5 allele reinforces an alternative splice site
Figure 4. Frequency of IRGM variants in five HapMap populations from Asia and Africa (YRI 120, MKK 145, LWK 145, JPT 88, CHB 88) and 2025 white
population controls from the 1958 MRC British birth cohort (BC1958).
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which removes 139 bp from the 50 untranslated region of the
IRGM transcript. The consequence of this interstitial deletion
is not known, but it may affect the stability of the transcript
or the rate at which it is translated.
A previous study (7) has shown that the risk haplotype at the
IRGM locus is associated with either a reduction or an increase
in IRGM expression, depending on the cell line analysed. We
find that the risk alleles 2308(GTTT)5, CNVdel and
21644ins are all significantly associated with a down-
regulation of IRGM expression in untransformed lymphocytes
from CD patients. Given the strong LD between all three
variants, a very large sample of individuals of known genotype
would be required to determine whether each of the variants
had independent effects on gene expression. It is possible
that other as yet unknown variants at this locus may have
different effects; the SNP 2261C.T (rs9637876) has
recently been reported to confer protection from tuberculosis
caused by infection with Mycobacterium tuberculosis (27).
Direct functional analysis of the effect of all these candidate
causal variants on IRGM expression is likely to be required
to fully resolve their contribution to CD pathogenesis.
The lack of association of the index SNPs or candidate causal
variants with CD in the Japanese population is intriguing.
This does not appear to be due to phenotypic differences,
since CD in Japanese patients is clinically indistinguishable
from Europeans. It is also unlikely to be due to insufficient stat-
istical power, unless the effect size is significantly smaller in
this population. An alternative explanation is that the contri-
bution of IRGM to pathogenesis requires gene–gene or gene–
environment interactions which are absent in the Japanese. It
is also possible that none of the variants tested, including the
CNV, are causal and that the causal variant at this locus arose
after the European–Asian split, as is the case for the major
CD susceptibility gene NOD2/CARD15 (28,29). A further
possibility relates to the much higher expression of IRGM we
observed in CHB and JPT HapMap samples than in the CEU
samples. If the variants studied here result in only a modest
decrease in IRGM levels, then the relative effect may be insuffi-
cient to influence disease risk in Japanese individuals, who
show significantly higher expression than Europeans. Conver-
sely, in European individuals, for whom we observed a much
lower baseline expression, these variants may result in a
larger relative effect that is sufficient to influence disease risk.
This would be consistent with the lack of correlation between
IRGM expression levels and risk haplotype in the JPT and
CHB cell lines.
In conclusion, we have shown that multiple sequence var-
iants upstream of the IRGM gene with potential gene regulat-
ory effects are strongly associated with CD and with reduced
IRGM expression in untransformed cells from CD patients.
The lack of association of these variants with CD in the Japa-
nese population suggests that they may have population-
specific effects on the pathogenesis, or that more recent,
un-described mutations may be responsible for the association
in European populations. A combination of genetic and func-
tional approaches will be required to fully understand the con-
tribution of this locus to the development of this form of
chronic inflammatory bowel disease.
MATERIALS AND METHODS
Patients and controls
More than 1800 patients with CD were recruited from special-
ist IBD clinics in London and Newcastle (30) after informed
consent and ethical review (REC 05/Q0502/127). 2000 Popu-
lation controls were obtained from the 1958 British Birth
Cohort, which includes subjects born in 1 week of March
1958 in England, Scotland and Wales (31). UK case–control
studies were restricted to white Caucasian individuals. Japa-
nese CD cases (484) and controls (933) are described else-
where (32). HapMap DNA samples were purchased from
Coriell Cell Repositories, Camden, NJ, USA.
Sequencing of the IRGM promoter region
A 2.9-kb region of genomic DNA upstream of IRGM encom-
passing the entire 50-UTR including the upstream exon 1 and
intervening intron, ERV9 LTR and promoter was amplified in
94 unrelated individuals (including 43 CD individuals with
known risk haplotype, 29 UC and 22 unaffected) using
8 pmol of each primer 50-ACAATGAGTGTGTGAAACA
GACCT-30 and 50-CATAGTGATGTTAACTGGTGTCCTG-
30, 1 PCR Master mix (Promega) and 25 ng of template
genomic DNA in a 10 ml reaction. PCR conditions were as
follows: 5 min at 958C followed by 35 cycles of 30 s at
958C, 30 s at 628C and 3 min at 728C with a final extension
step of 10 min at 728C. Subsequent ExoSAP-IT clean up
(USB Europe, Staufen, Germany) followed by forward and
reverse cycle sequencing was performed in ten independent
Table 5. Association analysis of IRGM variants in 484 Japanese CD cases and
933 Japanese controls
Variant Risk allele Risk allele frequency Pallele OR (95%CI)
Cases Controls
CNV Del 0.370 0.380 0.76 0.98 (0.83–1.14)
21644 Ins 0.370 0.380 0.62 0.95 (0.81–1.12)
2308 (GTTT)5
a 0.510 0.553 0.03 0.84 (0.72–0.98)
rs13361189 C 0.393 0.379 0.43 1.07 (0.91–1.26)
rs10065172 T 0.366 0.379 0.52 0.94 (0.81–1.11)
aNo (GTTT)4 alleles were observed in this population.
Figure 5. Quantitative analysis of IRGM expression by real-time PCR in lym-
phocytes from CD patients of defined genotype for CNV (2, 1 and 0 copies of
the CNV where 1 and 0 are the heterozygous and homozygous risk genotypes,
respectively) 21644 (D ¼ del allele, I ¼ risk insertion allele) and 2308
(where 2 GTTT repeats represent the non-risk allele and 5 GTTT
repeats represent the risk allele. Relative expression is measured by, and inver-
sely proportional to, mean DCt (see Materials and Methods).
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reactions using 8 pmol of each of the overlapping nested
sequencing primers (Supplementary Material, Table S2) and
0.25 ml of ABI BigDye v3.1 (Applied Biosystems) in a 5 ml
reaction volume and using standard conditions. Products
were analysed on an ABI3730xl DNA sequencer (Sequence
analysis, Applied Biosystems) and aligned to the published
genomic sequence using the Sequencher 4.7 package (Gene-
Codes).
Fine-mapping of the CNV
Fine-mapping of the CNV was performed on a custom Nimble-
Gen 385k array across a 300-kb interval encompassing the BAC
on the WGTP array on which the CNV was first identified (22).
The median spacing between probes was 45-bp. This custom
array also targeted a number of other CNVs, which are not
described here. The results confirmed that the CNV is a bi-allelic
polymorphism that comprises either the presence or absence of
20 kb of sequence on chromosome 5q. The non-ancestral del-
etion spans from 150 183 354 to 150 203 455 on chromosome
5 (NCBI36).These data were subsequently used to design PCR
primers, 50-TTGCTGATGGCATGATCTTC-30 and 50-ATA
TGGCGAGAGCAGCAACT-30 for amplifying and sequencing
the deletion breakpoint.
Genotyping
The regions flanking the IRGM 21644 and 2308 polymorph-
isms were amplified independently using 4 pmol of each of
the following primer pairs 50-AAATGGACCAATCAGCAGG
A-30 (50 labelled with 6-FAM fluorescent dye): 50-AGGGG
CCAGGTATTTGAGAC-30 and 50-TGCCCACAGATACG
ACAGAG-30 (50 labelled with HEX fluorescent dye): 50-GG
ACGCAGATATTGCAGTGA-30, respectively. The reaction
mix also included 1 PCR Mastermix (Promega) and 25 ng
of genomic DNA in a 10 ml reaction volume. PCR conditions
were as follows; 2 min at 958C followed by 30 cycles of 20 s
at 958C, 30 s at 608C and 30 s at 728C, with a final extension
step of 5 min at 728C.
The CNV upstream of IRGM was genotyped via
allele-specific PCR with a common forward primer and
two allele specific reverse primers. The common forward
primer (50-AACAGTGACCTATCTGAAAAGGAAA-30) was
50 labelled with 6-FAM fluorescent dye and complementary
to sequence immediately upstream of the copy number
region. Of the two allele-specific reverse primers, the one
complementary to sequence within the copy number region
immediately adjacent to the forward primer (50-TTGAAA
TTTTGTAGAGATTGCATTG-30) will only amplify if the
20 kb copy number variant sequence is present, and the
other complementary to sequence immediately downstream
of the copy number region (50-TGCAGGGTACTGACTG
TCCA-30) will only amplify if the 20 kb copy number sequence
is absent (deleted). The assay was validated by analysis of eight
HapMap samples of known CNV status (22) (2 copies:
NA07000, NA07348; 1 copy: NA11995, NA12874, NA18501;
0 copies: NA18545, NA18547, NA18555). All samples gave gen-
otypes consistent with CGH data. PCR products for all three
variants (CNV, 2308, 21644) were diluted 1 in 50, pooled for
each individual and separated via by capillary electrophoresis
on the ABI3730xl Genetic Analyser with 10 ml of HiDi
formamide and 0.125 ml of GS500LIZ size standard (both
Applied Biosystems). SNPs rs10065172 (L105) was genotyped
using validated Taqman assays (ABI), and allelic discrimination
was carried out via endpoint read on ABI7900HT Sequence
detection system. All genotypes at all variants were in
Hardy–Weinberg equilibrium (P. 0.01).
Quantitative analysis of IRGM expression
Lymphocytes from patients with CD, genotyped for all IRGM
and upstream variants, were harvested from 40 ml of peripheral
blood. Peripheral blood mononuclear cells were isolated by
Lymphoprep (Axis-Shield, UK) and cultured at a density of
2  106 cells/ml in RPMI (Sigma Aldrich, UK) supplemented
with 2 mM glutamine (Sigma Aldrich, UK) and 10% FCS
(Sigma Aldrich, UK) in 24-well plates for 2 h at 378C in a
humidified atmosphere with 5% CO2. After this time the non-
adherent cell fraction (lymphocytes) were removed and
washed twice in PBS. The cell pellet was then re-suspended in
0.5 ml RNAlater (Sigma Aldrich, UK), incubated for 24 h at
48C and then stored at 2808C. Whole RNA was extracted
from primary lymphocytes using the Ribopure kit (Ambion)
and quantified using the Agilent Bioanalyser RNA 6000 Nano
chip (Agilent Technologies UK Limited). cDNA synthesis
was performed on 500 ng per sample of whole RNA using
iScript cDNA Synthesis Kit (BIO RAD Laboratories, CA,
USA). HapMap RNA was purified from cells purchased from
Coriell Cell Repositories, Camden, NJ, USA.
Allelic imbalance assay. Sequencing of the exonic SNP
rs10065172 in cDNA and genomic DNA (gDNA) samples
was performed using standard procedure (see above) with
exonic primers flanking the SNP (sequences available on
request). Mean C and T peak heights in duplicate samples of
cDNA and gDNA from eight CD individuals sequenced for
SNP rs10065172 were estimated from sequence electrophero-
grams by Sequence Scanner Software v1.0 (Applied Biosys-
tems, Foster City, CA, USA). Comparison of the mean ratio
of C:T peak heights in cDNA versus gDNA were calculated
via the Wilcoxon signed rank test. A ratio of .1 indicates
higher expression of the C allele (33).
Real-time RT–PCR assays. Quantitative fluorescent real time
RT–PCR was carried out in triplicate on 1 ml of cDNA from
primary lymphocyte samples of 24 CD patients using custom
6-FAM labelled fluorigenic Taqman MGB probe (50-TG
CCCACAGATACGAC-30) and flanking primers 50-CCCG
CCTGATGAGCTTACTC-30 50-AAGAGGTTAAGGATGCA
GCTAATAGAG-30 and a parallel reaction with a GAPDH
Table 6. Quantitative trait analysis of IRGM risk variants and expression in
HapMap populations
Locus All African YRI MKK LWK CHB JPT
CNV 8.15  1026 5.41  1025 0.240 0.010 0.307 0.264
rs13361189 3.74  1027 2.29  1026 0.033 0.016 0.797 0.349
21644 0.024 0.087 0.461 0.094 0.371 0.294
2308 5.66  1025 4.38  1026 0.257 0.040 0.262 0.578
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endogenous control (Eurogentech Ltd, Southampton, UK). The
IRGM genotype of the 24 patients had been previously deter-
mined for each of the risk variants 21644 (11/8/5) 2308
(9/7/5) and CNV (10/8/5). Real-time Quantitative-PCR was
carried out on ABI7900HT system. Results were analysed via
the DCt method for relative cDNA quantitation (http://www3.
appliedbiosystems.com/cms/groups/mcb_support/documents/
generaldocuments/cms_042380.pdf). Briefly, a threshold fluor-
escence level was selected at which PCR amplification of the
target sequence was in the logarithmic phase and the cycle
number at which each sample PCR reaction crossed that
threshold was recorded (the threshold cycle or Ct). The relative
quantity of cDNA for the target gene in each individual (DCt)
was calculated as the difference between the mean Ct value for
the target and the mean Ct value for the endogenous control
and all were calibrated (normalised) with Ct values of cDNA
from a low-level expressing placental sample.
Alternative splicing of IRGM mRNA was investigated by
RT–PCR of cDNA from four individuals with three different
genotypes for the IRGM-308 variant [(GTTT)5/(GTTT)5,
(GTTT)5/(GTTT)2, (GTTT)2/(GTTT)2] using forward primer
50-GTCTCAAATACCTGGCCCCT-30 and reverse primer
IRGMPROM_PCR_rev (Supplementary Material, Table S2).
The identity of each cDNA species was confirmed by sequen-
cing of gel-extracted product.
Microarray expression analysis. Expression of IRGM and
ZNF300 in HapMap3 RNA samples was analysed on Illumina
human whole-genome expression arrays as previously
described (26), but using Illumina WG-6 v2 arrays.
Statistical analysis
Association analysis for qualitative (CD) and quantitative
(IRGM expression) trait loci, including conditional regression
analysis was performed using UNPHASED v3.0.12 (34), the
latter assuming a full haplotype model. Haploview v4.1 (35)
was used to calculate linkage disequilibrium coefficients (r2).
All other statistical analysis was performed using R v2.7.0
(www.r-project.org). Linear regression with repeated measures
was used to analyse IRGM expression (as estimated by DCt
values from Q-RT–PCR) with multiple replicates for each indi-
vidual. The relationship between IRGM expression (from Illu-
mina microarray data) and IRGM genotype in the different
HapMap populations was also analysed using linear regression.
Figure 6. Relative expression of IRGM in HapMap populations from Asia (JPT & CHB), Africa (YRI, LWK & MKK) and Europe (CEU) by microarray analysis
(26).
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